JPRN-UMIN000023639已完成未知
A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects - Transcranial MRgFUS Thalamotomy on Essential Tremor Subjects
Departments of Neurology and Neurosurgery, Hokuto Hospital0 个研究点目标入组 10 人开始时间: 2017年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 22years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Subjects with unstable cardiac status 2. Subjects exhibiting any behaviors consistent with ethanol or substance abuse 3. Severe hypertension 4. Subjects with standard contraindications for MR imaging 5. Known intolerance or allergies to the MRI contrast agent 6. Patient with severely impaired renal function and/or who is on dialysis 7. History of abnormal bleeding and/or coagulopathy 8. Receiving anticoagulant or antiplatelet therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage within one month of focused ultrasound procedure 9. Active or suspected acute or chronic uncontrolled infection 10. History of immunocompromise including those who are HIV positive 11. History of intracranial hemorrhage 12. Cerebrovascular disease 13. Subjects with uncontrolled symptoms and signs of increased intracranial pressure 14. Presence of any other neurodegenerative disease such as Parkinson-plus syndromes suspected on neurological examination 15. Anyone suspected to have the diagnosis of idiopathic Parkinson's disease 16. Presence of significant cognitive impairment 17. Subjects with life-threatening systemic disease 18. Subjects with a history of seizures within the past year 19. Subjects with presence or history of psychosis. Subjects with significant or active mood disorders including depression 20. Subjects with risk factors for intraoperative or postoperative bleeding 21. Subjects with brain tumors 22. Pregnancy or lactation 23. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia 24. Subjects who have been administered botulinum toxins for 5 months prior to Baseline 25. Subjects who have an Overall Skull Density Ratio of 0.35 or less as calculated from the screening CT
研究者
相似试验
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor SubjectsMedication Refractory Essential TremorJPRN-UMIN000033752Medical Corporation Tokushukai Shonanfujisawa Tokushukai Hospital10
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor SubjectsMedication Refractory Essential TremorJPRN-UMIN000019498Department of Neurosurgery, Osaka University School of Medicine10
已完成
不适用
Safety and effectiveness of TOPS™ SystemSingle Level Lumbar Spine Stenosis (with up to a grade 1 spondylolisthesis)SurgeryISRCTN47205504Premia Spine Ltd (Israel)10
招募中
4 期
The effect and safety of the drug Acyclovir in patients of Pityriasis rosea (a widespread red and scaly lesion following infection or drug intake)CTRI/2013/12/004240Institutional Medical College Kolkata24
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864EUCTR2018-003866-14-ESApexigen, Inc.174